Construction, expression and in vitro biological effects of idiotype Ig Fab fragment of B-chronic lymphocytic leukemia

Abstract

The purpose of this study was to construct expression vectors of idiotype (Id) SmIg in patients with B-chronic lymphocytic leukemia and to express them in E.coli to obtain recombinant Id, and to investigate the effect of the protein on the proliferation and secretion of IL-2 and IFN-γ of stimulated peripheral blood mononuclear cells (PBMC) in vitro. Light chain gene and Fd fragment of heavy chain gene were inserted into fd-tet-DOG2 vector to construct fd-tet-DOG2-Fab. Fab gene was further cloned into expression vector pHEN2 to construct the soluble expression vector pHEN2-Fab. After induction by IPTG, Fab protein was purified by Ni-NTA-chromatography. MTT was used to determine the effects of purified protein on the proliferation of stimulated PBMC in vitro and the concentrations of IL-2 and IFN-γ in the culture supernatants were detected by ELISA. The results showed that recombinant pHEN2-Fab expression vector was constructed successfully. Fab protein was expressed in positive clone after induced by IPTG and two specific bands at 24–25 kD position were observed by SDS-PAGE electrophoresis. Proliferation of PBMC could be induced by purified Fab and the concentrations of IL-2 and IFN-γ in culture supernatants were increased significantly after induction. It was suggested that the expression vector of SmIg Fab fragment was constructed successfully, and expressed and secreted from E. coli. The Fab protein could induce proliferation of PBMC and promote secretion of IL-2 and IFN-γ.

Keywords

B-chronic lymphocytic leukemia / Fab / idiotype / IL-2 / IFN-γ

References

[1] ChiorazziN., RaiK. R., FerrariniM.. Chronic lymphocytic leukemia. N Engl J Med, 2005, 352(8): 804-815

[2] BendandiM.. The role of idiotype vaccines in the treatment of human B-cell malignancies. Expert Rev Vaccines, 2004, 3(2): 163-170

[3] ZhuH. F., WangF., ZhangY., et al.. Cloning of Ig Fab genes of patients with chronic B lymphocytic leukemia and sequences analysis of their variable regions. Zhonghua Xue Ye Xue Za Zhi (Chinese), 2002, 23(9): 474-479

[4] RavandiF., O’BrienS.. Immune defects in patients with chronic lymphocytic leukemia. Cancer Immunol Immunother, 2006, 55(2): 197-209

[5] DingW., ZentC. S.. Diagnosis and management of autoimmune complications of chronic lymphocytic leukemia/small lymphocytic lymphoma. Clin Adv Hematol Oncol, 2007, 5(4): 257-261

[6] NeelapuS. S., GauseB. L., NikcevichD. A., et al.. Phase III randomized trial of patient-specific vaccination for previously untreated patients with follicular lymphoma in first complete remission: protocol summary and interim report. Clin Lymphoma, 2005, 6(1): 61-64

[7] WengW. K., CzerwinskiD., LevyR.. Humoral immune response and immunoglobulin G Fc receptor genotype are associated with better clinical outcome following idiotype vaccination in follicular lymphoma patients regardless of their response to induction chemotherapy. Blood, 2007, 109(3): 951-953

[8] BendandiM., Rodríguez-CalvilloM., InogésS., et al.. Combined vaccination with idiotype-pulsed allogeneic dendritic cells and soluble protein idiotype for multiple myeloma patients relapsing after reduced-intensity conditioning allogeneic stem cell transplantation. Leuk Lymphoma, 2006, 47(1): 29-37

[9] NeelapuS. S., MunshiN. C., JagannathS., et al.. Tumor antigen immunization of sibling stem cell transplant donors in multiple myeloma. Bone Marrow Transplant, 2005, 36(4): 315-323

[10] BertinettiC., SimonF., ZirlikK., et al.. Cloning of idiotype immunoglobulin genes in B cell lymphomas by anchored PCR and production of individual recombinant idiotype vaccines in Escherichia coli. Eur J Haematol, 2006, 77(5): 395-402